CAMBRIDGE, MA, November 9, 2017 -- The CEO of Aurora BioPharma, Robert Brooks, will attend the NYC Life Science Conference by ivyFON and Wheaton Ventures on November 9 – 10 at the W.R. Grace Building in New York City. The event attracts over 80 investors and 25 presenting companies, and features numerous informative panels.
Ivy Family Office Network (IVYFON) has been the leading peer to peer family office network since 2005. More than 35,000 investors, family offices and asset allocators have attended their events. They run Family Office forums in more than 25 cities around the world and operate on a continual basis in 20 of them. Their plethora of event types and a lightning fast initiative allow them to provide hyper local family office forums that restrict attendance by vendors, preserve family office privacy and provide up-to-the minute information on investment themes for attendees.
Wheaton Ventures is a private equity firm specializing in venture, public equity and private equity investments. The firm typically invests in healthcare, energy, financial services, technology, media, and natural resources sectors. Wheaton Ventures offices are located at The Helmsley Building in New York.
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy in solid tumors, with a diversified mid-stage clinical pipeline. Aurora's CAR T drug AU105 completed Phase I/IIa clinical trial in 16 Glioblastoma patients showing safety, tumor killing efficacy, double the median historic overall survival, with 3 patients alive after 5 years. Aurora's CAR T drug AU101 completed a Phase IIa trial in 6 Sarcoma atients, showing safety, tumor-killing and a Complete Response ---cancer free after 5 years. Aurora is planning a pivotal trial of its CAR T Cell therapy in Glioblastoma and Osteosarcoma.
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Aurora BioPharma, Inc.
Tel: (617) 674-7718
Fax: (617) 674-7701
SOURCE Aurora BioPharma, Inc.